NeoGenomics, Inc. (NEO)
NEO Stock Price Chart
Explore NeoGenomics, Inc. interactive price chart. Choose custom timeframes to analyze NEO price movements and trends.
NEO Company Profile
Discover essential business fundamentals and corporate details for NeoGenomics, Inc. (NEO) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Diagnostics & Research
IPO Date
16 Mar 2004
Employees
2.20K
Website
https://www.neogenomics.comCEO
Anthony P. Zook
Description
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
NEO Financial Timeline
Browse a chronological timeline of NeoGenomics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 27 Apr 2026
Upcoming earnings on 16 Feb 2026
Upcoming earnings on 4 Nov 2025
EPS estimate is $0.02.
Earnings released on 29 Jul 2025
EPS came in at $0.03 matching the estimated $0.03, while revenue for the quarter reached $181.33M , missing expectations by -1.37%.
Earnings released on 29 Apr 2025
EPS came in at -$0.08 falling short of the estimated -$0.02 by -300.00%, while revenue for the quarter reached $168.04M , missing expectations by -8.14%.
Earnings released on 18 Feb 2025
EPS came in at $0.04 surpassing the estimated $0.03 by +33.33%, while revenue for the quarter reached $172.00M , missing expectations by -0.34%.
Earnings released on 5 Nov 2024
EPS came in at $0.05 surpassing the estimated $0.01 by +316.67%, while revenue for the quarter reached $167.82M , missing expectations by -3.04%.
Earnings released on 29 Jul 2024
EPS came in at $0.03 surpassing the estimated $0.00 by +880.39%, while revenue for the quarter reached $164.50M , missing expectations by -1.28%.
Earnings released on 30 Apr 2024
EPS came in at -$0.02 falling short of the estimated -$0.01 by -59.24%, while revenue for the quarter reached $156.24M , missing expectations by -3.69%.
Earnings released on 20 Feb 2024
EPS came in at $0.03 surpassing the estimated $0.01 by +220.51%, while revenue for the quarter reached $155.55M , beating expectations by +1.98%.
Earnings released on 6 Nov 2023
EPS came in at -$0.06 surpassing the estimated -$0.07 by +14.29%, while revenue for the quarter reached $151.95M , beating expectations by +7.01%.
Earnings released on 8 Aug 2023
EPS came in at -$0.05 surpassing the estimated -$0.10 by +50.00%, while revenue for the quarter reached $146.92M , beating expectations by +6.91%.
Earnings released on 8 May 2023
EPS came in at -$0.09 surpassing the estimated -$0.14 by +35.71%, while revenue for the quarter reached $137.22M , beating expectations by +8.57%.
Earnings released on 23 Feb 2023
EPS came in at -$0.06 surpassing the estimated -$0.15 by +60.00%, while revenue for the quarter reached $138.71M , beating expectations by +6.72%.
Earnings released on 8 Nov 2022
EPS came in at -$0.14 surpassing the estimated -$0.19 by +26.32%, while revenue for the quarter reached $128.78M , beating expectations by +5.96%.
Earnings released on 9 Aug 2022
EPS came in at -$0.16 surpassing the estimated -$0.22 by +27.27%, while revenue for the quarter reached $125.07M , beating expectations by +1.74%.
Earnings released on 27 Apr 2022
EPS came in at -$0.20 surpassing the estimated -$0.23 by +13.04%, while revenue for the quarter reached $117.17M , beating expectations by +0.39%.
Earnings released on 23 Feb 2022
EPS came in at -$0.14 falling short of the estimated -$0.13 by -7.69%, while revenue for the quarter reached $125.73M , missing expectations by -0.01%.
Earnings released on 4 Nov 2021
EPS came in at -$0.08 matching the estimated -$0.08, while revenue for the quarter reached $121.34M , missing expectations by -4.15%.
Earnings released on 6 Aug 2021
EPS came in at -$0.01 surpassing the estimated -$0.05 by +80.00%, while revenue for the quarter reached $121.72M , meeting expectations.
Earnings released on 5 May 2021
EPS came in at -$0.04 falling short of the estimated -$0.01 by -466.57%, while revenue for the quarter reached $115.53M , beating expectations by +2.64%.
Earnings released on 24 Feb 2021
EPS came in at $0.14 surpassing the estimated $0.06 by +133.33%, while revenue for the quarter reached $126.00M , beating expectations by +21.21%.
Dividend declared on 15 Dec 2020
A dividend of $0.40 per share was announced, adjusted to $0.40. The dividend was paid on 30 Dec 2020.
Earnings released on 27 Oct 2020
EPS came in at $0.06 surpassing the estimated $0.04 by +57.89%, while revenue for the quarter reached $125.44M , beating expectations by +50.00%.
NEO Stock Performance
Access detailed NEO performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.